uniQure shares steady after FDA momentum, Huntington’s filing on radar

uniQure N.V. shares on the Nasdaq held much of Wednesday’s big jump in premarket trade Thursday. The U.S. FDA has cleared a route for the Netherlands-based gene-therapy firm to pursue approval of its experimental Huntington’s disease drug, AMT-130. The stock finished at $48.16 on Wednesday, climbing 78.4% from $26.99 a day before.

Biotechnology · NASDAQ:QURE · Stock Market
uniQure shares steady after FDA momentum, Huntington’s filing on radar

uniQure Gets Go-Ahead From FDA for AMT-130 Huntington’s Gene Therapy Application

uniQure said Wednesday the U.S. Food and Drug Administration will let it use three-year data from its early Huntington’s gene therapy trial as the basis for an accelerated approval filing, changing course in the dragged-out regulatory battle over the therapy. The company will go ahead with a biologics license application in the third quarter. That application is the standard FDA process for marketing a biologic drug in the U.S.
17 June 2026
·
Regentis Biomaterials Stock Falls Premarket After 506% Surge on Scrapped Share Offering

Regentis Biomaterials Stock Falls Premarket After 506% Surge on Scrapped Share Offering

Regentis Biomaterials Ltd. shares turned lower in early Tuesday trading after a huge Monday rally that was driven by the removal of a near-term share-sale overhang. RGNT closed June 15 at $9.40, up 506.45% on the day, before Google Finance showed the stock indicated at $6.80 in premarket trading, down 27.66%. The same quote page listed an intraday high of $15.50, a low of $1.69 and a market capitalization of about $48.69 million, underscoring how thinly traded small-cap biotech and medtech names can swing sharply when news changes the supply-demand picture for shares.
16 June 2026
··
Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus

Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus

Intellia Therapeutics shares surged Monday as investors reacted to additional late-stage data for lonvoguran ziclumeran, or lonvo-z, the company’s one-time CRISPR-based therapy for hereditary angioedema, a rare genetic disease that causes unpredictable and potentially life-threatening swelling attacks. The Nasdaq-listed biotech was recently trading at $14.92, up roughly 23%, with volume far above normal levels. Stocks rise when new information increases expected future sales, profits or approval odds; they fall when investors see lower odds, higher risks or dilution.
16 June 2026
··
Regentis Biomaterials Jumps After Firm Scraps Public Offer

Regentis Biomaterials Jumps After Firm Scraps Public Offer

Shares of Regentis Biomaterials Ltd. jumped on NYSE American Monday after the company said in an SEC filing it's withdrawing its Form F-1 registration. The form allows foreign firms to list in the U.S., but Regentis said the offer won't go forward and no shares were sold because the F-1 wasn't effective. RGNT traded up about 677% at $11.65. The session saw the stock swing between $1.51 and $15.43 and over 161 million shares changed hands.
15 June 2026
··
Park Ha Biological Technology Stock Surges Premarket as BYAH Volatility Grabs Traders

Park Ha Biological Technology Stock Surges Premarket as BYAH Volatility Grabs Traders

Park Ha Biological Technology Co., Ltd. shares were set for another dramatic session Friday, with BYAH trading at $2.40 in premarket dealings, up 128.57% from Thursday’s close, according to StockAnalysis data sourced from S&P Global Market Intelligence. Premarket trading means buying and selling before the regular Nasdaq session opens; it can be thin and volatile, so early prices may not reflect where the stock will trade after 9:30 a.m. in New York.
12 June 2026
··
Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax shares dropped hard Tuesday, despite positive late-stage trial results for its obefazimod drug. Investors focused on reported cancer and dysplasia cases in patients on the higher dose. The stock traded at 63.10 euros on Euronext Paris, well below Monday’s closing price of 111.80 euros, after touching 62.80 euros earlier. Over in the U.S., its Nasdaq ADRs were last at $72.86, down some 44% late in the session.
2 June 2026
····
Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines Inc shares gained in early U.S. premarket trading Monday after late-stage trial results reported its experimental pill for pancreatic cancer almost doubled survival against chemo. RVMD was last seen at $157.48, up $2.93, or 1.9%, ahead of the regular Nasdaq open. The company’s market cap hovered at about $31.2 billion. Nasdaq’s 2026 calendar does not list June 1 as a holiday—Memorial Day shows May 25 and Juneteenth June 19 as closures.
1 June 2026
···
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant shares closed 35.3% higher at $35.56 on Wednesday after the biotech company reported encouraging 16-week data for its experimental rheumatoid arthritis drug, IMVT-1402, a move that made the stock one of the day’s standout U.S. healthcare gainers. Roivant Sciences, Immunovant’s majority owner, also rose sharply, closing about 14.9% higher at $32.41.
20 May 2026
···
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

ImmunityBio’s push to expand Anktiva’s use in bladder cancer is back before the FDA, after the agency accepted a supplemental biologics license application. The FDA set a target action date for Jan. 6, 2027. ImmunityBio wants approval for Anktiva used with Bacillus Calmette-Guérin, or BCG, for BCG-unresponsive non-muscle invasive bladder cancer patients with papillary disease and no carcinoma in situ.
20 May 2026
·
Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Inc. shares jumped in heavy U.S. trading on Tuesday after the molecular diagnostics company said it had completed a strategy for a possible Ebola assay tied to the Bundibugyo virus outbreak in the Democratic Republic of Congo and Uganda. The stock was recently up 51% at $2.07, after touching $2.73, on volume above 94 million shares; the iShares Russell 2000 exchange-traded fund, a small-cap stock basket, was down about 1.2%.
19 May 2026
···
1 … 3 4 5 6 7 … 22
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

82/100
View full portfolio
Editorial model selection. Not personalised advice.